ABSTRACT
INTRODUCTION
Inborn errors of metabolism (IEM) individually are rare but collectively are common. In IEMs single gene defects are responsible for the abnormalities in the synthesis or catabolism of proteins, carbohydrates or fats by way of defective enzymes or transport proteins, resulting in a block of metabolic pathway. The male to female ratio is 1:1 for X-linked dominant if transmission is from mother to child (1) . Effects are due to toxic accumulations of the substrates before block, intermediates from alternative metabolic pathways, defects in energy production and use caused by a deficiency of products beyond the block or a combination of these metabolic deviations. Figure I shows the theoretical consequences of metabolic disorders. Nearly every metabolic disease has several forms that vary in age of onset, clinical severity and often mode of inheritance. Proper history from parents has a role in suspecting IEM. Parental consanguinity increases the chance of autosomal recessive IEM (2) .
For evaluating an IEM the following five important aspects should follow:
1.
History/ Family History -We should note whether the neonate was born to a consanguineous parents or not and also check previous history of older sibling like fetal deaths or miscarriages or genetically affected siblings and also note the pedigree for about two generations.
2.
Physical examination like dermatitis, alopecia, facial dysmorphia, cataract etc. 3.
Initial screening tests includes Complete blood count, Electrolytes level, Glucose, Ammonia, Lactate, Lactate/ Pyruvate ratio, Reducing substances, organic acids, Amino acids, Ketones.
4.
Advanced screening tests: The test is performed on the basis of clinical context which includes long chain fatty acids, MPS separation and speciation, quantitation of amino acids, organic acids, carbohydrate and other metabolites.
5.
Definitive diagnostic tests: To confirm the disorder detected, a specific enzyme assays in leucocytes, plasma/serum or red cells, immunoassays and DNA/ Mutation based analysis will be tested.
The diagnosis of metabolic disorders is challenging because of : 1. The episodic nature of metabolic illness. 2. The wide range of clinical symptoms that is also associated with more common conditions. 3. The low incidence of these disorders. 4. The consequent lack of experience among the pediatric sub-specialties and 5. The need for specialty testing (3).
Individual IEM are rare disorders, most having an incidence of less than 1 per 100,000 births. However, when considered collectively, the incidence may approach 1 in 800 to 2500 births. In one review of cases of IEM diagnosed in British Columbia (a predominantly Caucasian population) between 1969 and 1996, estimates of incidence of various classes of disorders were as follows (4) (6) . IEM can affect any organ system and usually affect multiple A detailed classification is beyond the purview of this review. Hence only few examples are mentioned.
Clinical findings
Common considerations in determining whether to screen for disorders are:
1.
A disease that can be missed clinically at birth.
2.
A high enough frequency in the population.
3.
A delay in diagnosis will induce irreversible damages to the baby.
4.
A simple and reasonably reliable test exists.
5.
A treatment or intervention that makes a difference if the disease is detected early (8) .
Screening is a basic tool for clinically suspected cases of inborn metabolic disease by a simple economical and effective technique like paper chromatography, TLC and some biochemical tests. However, it is not reasonable to make firm decision on the basis of screening test. HPLC is an acceptable technique to analyze and quantification of amino acids, organic acids and metabolites from biological fluids. Tandem Mass Spectrometry (TMS), GC/MS are the advanced technique for diagnosing metabolic disorders for confirmation. The Acylcarnitines in blood reflect the primary accumulating mitochondrial acyl-CoA metabolites in disorders of fatty acid and amino acid catabolism. Thus a acylcarnitine "profile" will recognize almost all of the defects in these pathways using the advanced technique like TMS (3). Advanced chemical diagnosis using GC/MS has also become an important part of the routine service. About 115 inherited organic and aminoacid disorders are diagnosed by employing a combination of GC/MS and an aminoacid analyzer and more than 910 cases and 80 inherited aminoacid metabolic diseases have been successfully identified since 1978. Among them lactic acidosis was the most frequently found inborn organic metabolic error comprising approximately 40% of total disorder (9).
The study report indicates the collective incidence of IEMs detected using qualitative and quantitative assays and consequently confirmed by confirmation test wherever possible. This study emphasizes the importance to diagnosis for IEM that helps early intervention in affected neonates. 
STUDY REPORTS
We retrospectively reviewed eight hundred and sixty nine cases for age groups 40.2% <1 year, 19.9% 1-3 years, 13.5% 3-5 years, 18.4% >5Year and 8.0% adults were received in duration of two year with presenting symptoms of IEMs. 4 cc EDTA blood and urine of about 10cc were collected and when necessary C.S.F samples were also collected and stored at 4-8°C till the respective assay was performed the same day or the next day.
The important clinical findings as indicated by referrals of the eight hundred and sixty nine cases has 4.3% poor feeding, 6.4% lethargy, 4% failure to thrive, 10.6% seizures, 6% delayed milestones, 1.7% behavior disturbances, 2.8% irritability, 0.6% ataxia, 2.8% abnormal muscle tone, 0.92% attention deficit, 1.07% coma, 1.53% hepatomegaly, 0.61% splenomegaly, 7.2 % metabolic acidosis, 2% apnea, 0.92% skeletal abnormalities, 1.4% microcephaly, 2.2 % dysmorphic facial features, 4.4% hyopglycemia and 2.3% hyperammonemia. In 6.9% of the total cases (as indicated by referring clinician) consanguinity was noted.
The initial evaluation comprised of a complete blood count (CBC), measurement of serum levels of lactic acid, electrolytes, glucose, liver and kidney functions and plasma ammonia. Renal function was assessed by measurement of BUN and Creatinine. Hepatic functions were assessed by determinations of bilirubin, transaminases and Prothrombin time (8) . All clinical data pertinent to the index case including current treatment regimen were collected. For samples referred from outside above mentioned data was sought. Cases where such data was not available are not considered in this review. Wherever a consanguinity or family history was evident, relevant details were noted.
All samples were subjected to a metabolic screening profile, the panel comprising of estimations of carbohydrates, amino acids, mucopolysaccharides, porphyrinuria, bile salts and pigments and organic acid metabolites. Techniques applied were High Performance Liquid Chromatography (HPLC), Gas Chromatography-Mass Spectrophotometry (GC-MS), Partition chromatography and fully automated cellulose acetate electrophoresis. Tandem Mass Spectrometry (TMS) was used for carnitine & Acyl Carnitines analysis.
The enzyme assays were performed with leukocytes and erythrocytes when a specific enzyme was needed for confirmation. This assisted confirmation of diagnosis and decision on further treatment and management of the case. The substrate is converted to product, the accumulation of product obtains in case of loss of feed back inhibition leads to metabolic disorders. 4. Due to metabolic defects, substrate is not converted to product and accumulation of substrate leads to systemic effects. 5. If substrate is not converted to product due to enzyme or cofactor deficiency, it enters to alternative pathway and produce toxic metabolites which lead to systemic effects in turn causes presenting features of inborn errors of metabolism. 
Inborn Errors of Metabolism
usually non-specific and similar to those seen in infants with sepsis. An inborn error of metabolism should be considered in the differential diagnosis of a severely ill neonatal infant, and special studies should be undertaken if the index of suspicion is high. It has been shown that if detected early complication in these disorders could be easily prevented with dietary restriction of the offending food constituent of metabolite (10) .
All the eight hundred and sixty nine that were considered for the study were first subjected to screening for a possible IEM. Among them about 2.65% of the cases indicated the presence of IEM. The positive cases were confirmed by performing the relevant confirmatory tests. Even though IEM are rare, the results emphasize that they are collectively common. Most of the metabolic disorders can be detected in the neonatal period. For Tyrosinemia type I, urinary succinyl acetone was not standardized in our lab at the stage, when the samples had arrived. Depending on the clinical symptoms, clinician inputs and high tyrosine level, the case was presumptively recorded as a Tyrosinemia Type I. Detecting a disorder much earlier means early initiation of treatment and possibly retards the progression of the disorder. Some of these disorders tend to become difficult to manage when detected too late and some could be fatal too.Adding to the burden is the lack of adequate awareness about these disorders and the existing treatment modalities among the clinical fraternity and misconceptions about them in the general population (11) .
With investigation like TMS and GC-MS available today, a diagnostic revolution may not be far away. The TMS alone can detect 35-40 metabolic disorders and has revolutionized the concept of newborn screening in the developed countries. This may be difficult for developing countries to follow given the socio-economic considerations. HPLC and GC-MS for IEM are probably to be adapted in developing countries for reasons of affordability without compromise on the quality. The high numbers of screen positives observed in the screening panel of tests is of fundamental importance for directing the clinical investigation. It depends on an intimate association between the interpretations of the biochemical and metabolic tests and a specialized multidisciplinary clinical investigation. Inborn Fabrys disease D-Galactosidase Episodes of pain, particularly in the hands and feet, clusters of small, dark red spots on the skin called angiokeratomas, cloudiness of the front part of the eye (corneal opacity).
errors of metabolism must be suspected whenever a patient presents metabolic disturbances or neurological manifestations without a determined cause. Always correlate the metabolic screen results with the clinical picture because, if the patient has liver disease and tubular defects aminoaciduria will be present and if it is hypo perfusion, also show lactic acidemia. Some of the drugs may also interfere with the analysis for eg. Valporate intake leads to ketone positive on the urine dipstick tests and Topiramate, Acetazolamide might produce lactic acidemia. A single negative test should not be used to exclude IEM in all cases. The time of testing, particularly in episodic disorders, stress testing following well defined protocol, clinical picture and details of drugs taken should be considered for arriving at a final diagnosis. Lack of indigenous External Quality Assurance programs is a cause of worry (12) .
IEM are typically genetic disorders, family members need to be counseled about the probability of the next offspring being affected. It is of utmost importance to families who have a known history of such occurrences (13) . Genetic counseling is assuming significance in India too (14) . The diagnosis of an inborn error of metabolism often needs to be established quickly in order to prevent death or permanent neurological sequelae.
An IEM could be a diagnosis of inclusion rather than exclusion. For the small number of babies who may have one of these disorders, appropriate and timely care can make a lifetime of a difference!
